TORONTO, Nov. 4, 2024 /CNW/ -- Compugen Inc., the nation's largest privately-owned and operated Technology Ally, is proud to announce the acquisition of SynerSolutions Technologies Inc., a leader in ...

HOLON, Israel, March 9, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, reported today updated data from its ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Compugen (CGEN – Research Report), with a price target of $7.00. Geoff Meacham has given his Buy rating due to a combination of ...

HOLON, Israel, Jan. 8, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the appointment of ...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with ...

RICHMOND HILL, ON, Jan. 22, 2024 /PRNewswire/ -- Compugen Inc., the nation's largest privately-owned and operated Technology Ally, is pleased to announce MarketDesign Consulting Founder + CMO Kara ...

– Gilead Will Have Exclusive Rights to Later Stage Development and Commercialization of Anti-IL18 Binding Protein Antibodies with Potential to Treat Various Tumor Types – – Gilead to Make $60 Million ...

TEL AVIV, Israel--(BUSINESS WIRE)-- Compugen Ltd. (NASDAQ: CGEN) announced today that administration of CGEN-15001 in an animal model of rheumatoid arthritis (RA) dramatically ameliorates the clinical ...

Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today presented new data for its preclinical CGEN-15029 program demonstrating the potential for the development of new cancer ...

TORONTO, Nov. 4, 2024 /PRNewswire/ -- Compugen Inc., the nation's largest privately-owned and operated Technology Ally, is proud to announce the acquisition of SynerSolutions Technologies Inc., a ...